Healthcare Industry News: spinal muscular atrophy
News Release - December 8, 2009
Stem Cell Based Treatment for Spinal Muscular Atrophy Receives Orphan Drug DesignationCalifornia Stem Cell, Inc. And Families Of spinal muscular atrophy Reach Significant Milestone In Development Of Motor Neuron Treatment For SMA
IRVINE, Calif.--(HSMN NewsFeed)--California Stem Cell, Inc. (CSC) and Families of spinal muscular atrophy (FSMA) announced today that the FDA has granted orphan drug designation to MOTORGRAFT™, a stem cell-derived motor neuron product, for the treatment of spinal muscular atrophy (SMA).
Orphan drug designation, granted by the FDA Office of Orphan Products Development, provides several incentives to companies in the private sector developing novel drugs or biologics to treat diseases with relatively small market potential. These include seven years market exclusivity following FDA approval, clinical trial design assistance, reduced user fees and tax credits.
CSC developed MOTORGRAFT™ as a stem cell-derived motor neuron replacement product for the treatment of SMA. Pre-clinical GLP safety and efficacy studies, funded significantly by the Families of spinal muscular atrophy and conducted by Professor Hans S. Keirstead of the University of California at Irvine, have demonstrated safety and functional benefit in several animal models.
SMA, the leading genetic killer of infants, causes the deterioration of the muscles that control crawling, walking, swallowing and breathing and affects approximately 1 in 6000 babies born. In the US approximately 7.5 million people (1 in 40) are carriers of the defective gene. There are no currently approved therapies for the treatment of SMA.
CSC recently completed a formal pre-IND meeting with the FDA to discuss the clinical and regulatory pathway for submission of an application to initiate human trials using this therapy for the treatment of SMA Type I. The company expects to file an IND to begin a Phase I safety study in 2010.
“We are extremely encouraged to receive orphan-drug designation for MOTORGRAFT™,” said Chris Airriess, CSC’s Chief Operating Officer, “this is a major milestone in realizing our commitment to find a treatment for SMA.”
“Families of SMA is pleased to see this promising therapy advancing towards clinical trials,” said Jill Jarecki, Research Director for FSMA, “Orphan Designation will provide CSC with all the opportunities afforded by Orphan Drug Act of 1983, which is intended to facilitate a close working relationship between regulatory agencies and companies with the aim of accelerating the drug development and approval processes for rare diseases.”
About California Stem Cell, Inc. (www.californiastemcell.com):
California Stem Cell, Inc. is a privately held company focused on the manufacture of high-purity human cells for drug development and clinical application. Since its founding in 2005, CSC has developed and has intellectual property surrounding methods for scalable production of human motor neurons, neuronal progenitors, and cardiomyocyte progenitors cells at its Irvine, California facility. CSC is currently in the pre-clinical development stage of stem cell-derived therapies for spinal muscular atrophy (SMA), ALS and spinal cord injury.
About Families of spinal muscular atrophy (www.fsma.org):
Families of SMA is a non-profit 501(c)3 tax exempt organization with 27 Chapters throughout the United States and over 65,000 members and supporters. Families of SMA funds and directs the leading SMA research programs. The successful results and progress from basic research to drug discovery programs to clinical trials provide real hope for families and patients.
Source: California Stem Cell
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.